Marina retweeted
I usually share the latest evidence. Many articles, however, can be impactful long after publication. I will start sharing some in a new feature: #AgelessGems💎. The first: a review by @GeorgeSledge51 on curing MBC. Thought provoking, balanced, unmissable. ascopubs.org/doi/full/10.120…
Marina retweeted
We’ve got another BEGINNER TRACK walkthrough for you! RSVP today and join Scientist Erin Howe, PhD for a deeper dive into racial and health disparities, side effects, and symptom management.
graspcancer.org/event/sabcs2…
#sabcs #sabcs2025 #GRASP #GRASPPosterWalkthrough #beginnertrack
Marina retweeted
🔥 A 25-year paradigm challenged in early BC: lidERA shows a giredestrant, a next generation oral SERD, outperforming aromatase inhibitors
iDFS HR 0.70
DDFS HR 0.69
This is really a breakthrough❗️
My take home on clinical implications
👉 High risk: CDK4/6-AI remains standard (more mature trial results). CAMBRIA 2 will define the role of CDK4/6-SERD combo
👉 Intermediate/high risk: SERD might be preferred (with more mature data) to CDK4/6. Is combo better? What about sequencing them (CAMBRIA1, EMBER4, ELEGANT)?
👉Intermediate risk: SERD preferred to CDK4/6
Marina retweeted
Lidera is a big step forward with a new endocrine agent in early-stage ER+ breast cancer
Lots of questions to address, but so important for patients!!!
@OncoAlert #SABCS25
Marina retweeted
HER2CLIMB-05 shows addition of tucatinib to maintenance HP, after median 6 cycles THP, improved mPFS 8.6 mos to 24.9 mos. Benefit more pronounced in HR-, but HR+ benefits as well. #SABCS25 @ErikaHamilton9 @OncoAlert
Marina retweeted
A new chemo free maintenance option for patients with HR+ & HR- HER-2 + disease in the 1st line setting post induction chemo that can provide a meaningful benefit in excess of 2 years is a win for our patients!
@SABCSSanAntonio @OncBrothers @OncoAlert @SarahCannonDocs
Adding tucatinib to standard maintenance therapy led to progression-free survival of more than two years in patients with HER2-positive metastatic breast cancer, according to results of the HER2CLIMB-05 trial presented by Dr. Erika Hamilton at #SABCS25 brnw.ch/21wYeG1
Marina retweeted
The billion dollar question: should we sequence ADCs for treating MBC? Proud to join @JoshDragoMD in this @NEJM debate, where we review the data in support and against the sequential use of ADCs. Open access — read it here: nejmgroup.org/wp-content/upl…
Marina retweeted
WOW! 🤩
Just fantastic to see this slide showing visually what we all know.
Pace of improvement in breast cancer is fast 🏎️!
👏 to all researchers, participants on trials, and our @FDAOncology colleagues who do an unbelievable amount of work for these approvals!
#SABCS25
Marina retweeted
@ErikaHamilton9 presents primary results from HER2CLIMB-05: adding tucatinib to 1L maintenance HP significantly improved PFS; most benefit in ER-/HER2+ disease (delta 12 mo). More diarrhea and liver tox with tucatinib. New SoC maintenance option after induction for ER-/HER2+ MBC!
Marina retweeted
In our retrospective Flatiron data presented at #SABCS24, T-DM1 did seem to outperform a second topo1 ADC after progression on prior T-DXd.
Marina retweeted
Evolution of HER2 testing over 40 yrs.
IHC lacks the dynamic range to predict outcomes with T-DXd, yet novel quantitative assays are emerging.
We presented data with HS-HER2 to predict T-DXd activity at #ESMO24. More data coming at #ASCO25.
Stay tuned.
nature.com/articles/s41571-0…
Marina retweeted
We have good evidence that leaving lymph nodes behind does not necessarily compromise outcomes. Could we push the limit & leave the tumor unresected in some responders? Early days, but fascinating concept. Congrats to the authors for this important report! jamanetwork.com/journals/jam…
Marina retweeted
Treatment Algorithm: This is the algorithm we’ve used during our 🗣️ w/ @KalinskyKevin for HR+ #BreastCancer!
#OncTwitter #bcsm #MedTwitter @CancerNetwrk @OncoAlert
Treatment Algorithm series: 🗣️ w/ @KalinskyKevin on HR+ #BreastCancer
✅ Adj CDK4/6i & PARPi
✅ NGS🎯
✅ ADC sequencing
Full discussion:
⭐️ oncbrothers.com/HRpositive-a…
⭐️ cancernetwork.com/treatment-…
⭐️ “Oncology Brothers” podcast
#bcsm #OncTwitter #MedTwitter @CancerNetwrk
Marina retweeted
The HMV program has given so many of us an entree into #mbc advocacy — for anyone living with MBC, I highly recommend it! #bcsm
Are you living with #metastatic #breastcancer? Do you want to advocate, raise awareness, and connect with others living with stage IV? We are now accepting applications for our Hear My Voice Metastatic Advocacy Program. Learn more and apply by January 29: bit.ly/3tEqyP9
Marina retweeted
Wrapping up another fantastic #SABCS!
Amazing, practice-changing data were presented.
I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!
#SABCS24 @OncoAlert
Marina retweeted
Small preview from Wednesday’s #SABCS24 session on the future of ADCs
Question: what do all these ongoing phase 3 ADC trials have in common?
🗓️ Dec 11, 3.30 pm, Hemisfair Ballroom 1-2
Honored to moderate the #SABCS24 People’s Choice session on the future of ADCs
We will review in depth the nuances of ADCs MoA, clinical use, development strategies.
And we will try guessing ADC’s future(s).
Make sure not to miss it!
🗓️Dec 11, 3.30 pm
sabcs.org/FullProgram
Marina retweeted
Really proud of my work wife (@itsnot_pink) filling the shoes of the late Anne Loeser - the driving force & founder of @the_rightdose. She leaves a legacy that improves the lives of MBC patients who are on treatment indefinitely through drug dose optimization.
#SABCS2024 #bcsm
Marina retweeted
There is an ongoing trial (STOPHER2) to look at stopping tx in people with HER2+ MBC who have been NED for a while, and there has been a study looking at changes in ctDNA with time in ER+ but I’m not aware of one looking at stopping tx if ctDNA undetectable . #SABCS24
Marina retweeted
Did Michelangelo paint a woman with breast cancer in the Sistine Chapel in Rome?🇮🇹
Nice article in @TheBreastOnline👇🏻
The breast has consistently held a significant role in artistic representations and, in this case, also in its pathologies
@OncoAlert
sciencedirect.com/science/ar…
